| DrugRepV_0276 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/New Jersey/15/2007 |  | Relative fluorescent unit | Decrease (50 %) | Approved | 26833677 |
| DrugRepV_0277 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/Netherlands/026/2008 | | Relative fluorescent unit | Decrease (50 %) | Approved | 26833677 |
| DrugRepV_0278 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/Netherlands /049/2008 | | Relative fluorescent unit | No significant effect (50 %) | Approved | 26833677 |
| DrugRepV_0279 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/Brisbane/59/2007 | | Relative fluorescent unit | No significant effect (50 %) | Approved | 26833677 |
| DrugRepV_0280 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/New Jersey/15/2007 | | Plaque assay | Decrease (10 %) | Approved | 26833677 |
| DrugRepV_0281 | Dorzolamide | Sensory Organ | Open-angle glaucoma and ocular hypertension | Influenza virus | A/Brisbane/59/2007 | | Plaque assay | No significant effect (NA %) | Approved | 26833677 |
| DrugRepV_0614 | Dipivefrin | Sensory Organ | Glaucoma | Lassa virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (90 %) | Approved | 23577127 |
| DrugRepV_0634 | Dipivefrin | Sensory Organ | Glaucoma | Lassa virus | Josiah | NA | Real-time PCR | No significant effect | Approved | 23577127 |
| DrugRepV_0653 | Dipivefrin | Sensory Organ | Glaucoma | Marburg virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (90 %) | Approved | 23577127 |
| DrugRepV_0677 | Dipivefrin | Sensory Organ | Glaucoma | Ebola virus | GP derived Pseudovirus | NA | Luciferase reporter assay | Decrease (94 %) | Approved | 23577127 |
| DrugRepV_0699 | Dipivefrin | Sensory Organ | Glaucoma | Ebola virus | EBOLA-eGFP | NA | Fluorescence-based assay | No significant effect | Approved | 23577127 |
| DrugRepV_0850 | Olopatadine | Sensory Organ | Allergic conjunctivitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (57.77 %) | Approved | 27476412 |
| DrugRepV_0871 | Methazolamide | Sensory Organ | Glaucoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (54.695 %) | Approved | 27476412 |
| DrugRepV_0873 | Carbachol Chloride | Sensory Organ | Glaucoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (58.395 %) | Approved | 27476412 |
| DrugRepV_0890 | Acetazolamide | Sensory Organ | Edema | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.035 %) | Approved | 27476412 |
| DrugRepV_0912 | Nepafenac | Sensory Organ | Inflammation associated with cataract surgery | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.565 %) | Approved | 27476412 |
| DrugRepV_0950 | Atropine Sulfate Monohydrate | Sensory Organ | Cholinesterase | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (56.08 %) | Approved | 27476412 |
| DrugRepV_0964 | Pilocarpine Hydrochloride | Sensory Organ | Xerostomia | Glaucoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (50.575 %) | Approved, Investigational | 27476412 |
| DrugRepV_0987 | Epinastine Hydrochloride | Sensory Organ | Allergy and conjunctivitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.33 %) | Approved | 27476412 |
| DrugRepV_1006 | Bimatoprost | Sensory Organ | Ocular Hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.62 %) | Approved | 27476412 |
| DrugRepV_1058 | Proparacaine Hydrochloride | Sensory Organ | Ophthalmic anesthetic | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.315 %) | Approved, Vet approved | 27476412 |
| DrugRepV_1097 | Tropicamide | Sensory Organ | Mydriasis and Cycloplegia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (55.195 %) | Approved | 27476412 |
| DrugRepV_1100 | Acetylcholine Chloride | Sensory Organ | Ophthalmological Disease | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (51.43 %) | Approved | 27476412 |
| DrugRepV_1129 | Fluorometholone | Sensory Organ | Inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.275 %) | Approved, Investigational | 27476412 |
| DrugRepV_1138 | Travoprost | Sensory Organ | Glaucoma or ocular hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (37.805 %) | Approved | 27476412 |
| DrugRepV_1146 | Cyclopentolate | Sensory Organ | Mydriasis and cycloplegia | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (47.525 %) | Approved | 27476412 |
| DrugRepV_1155 | Levobunolol Hydrochloride | Sensory Organ | Glaucoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (49.12 %) | Approved | 27476412 |
| DrugRepV_1181 | Brimonidine | Sensory Organ | Glaucoma | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.265 %) | Approved | 27476412 |
| DrugRepV_1249 | Dorzolamide Hydrochloride | Sensory Organ | Open-angle glaucoma and ocular hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (48.595 %) | Approved | 27476412 |
| DrugRepV_1273 | Bromfenac | Sensory Organ | Non-steroidal anti-inflammatory agent | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (45.755 %) | Approved | 27476412 |
| DrugRepV_1278 | Latanoprost | Sensory Organ | Glaucoma or ocular hypertension | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (46.57 %) | Approved, Investigational | 27476412 |
| DrugRepV_1375 | Cysteamine Hydrochloride | Sensory Organ | Radiation sickness, cystinosis and cystinurea | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (44.955 %) | Approved | 27476412 |
| DrugRepV_1402 | Loteprednol Etabonate | Sensory Organ | Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.55 %) | Approved | 27476412 |
| DrugRepV_1495 | Homatropine Methylbromide | Sensory Organ | Peptic ulcer | Gastric ulcer | Duodenal ulcer | Zika virus | MEX_I_7 | NA | Fluorescence-based assay | Decrease (43.29 %) | Approved | 27476412 |
| DrugRepV_2209 | Proparacaine Hydrochloride | Sensory Organ | Ophthalmic anesthetic | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.83586814 %) | Approved, Vet approved | 27742486 |
| DrugRepV_2218 | Trifluridine | Sensory Organ | Primary keratoconjunctivitis and Herpes simplex keratitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.43774052 %) | Approved | 27742486 |
| DrugRepV_2219 | Oxymetazoline Hydrochloride | Sensory Organ | Eye irritation | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (7.399478 %) | Approved, Investigational | 27742486 |
| DrugRepV_2248 | Tropicamide | Sensory Organ | Mydriasis and Cycloplegia | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (6.04488039 %) | Approved | 27742486 |
| DrugRepV_2364 | Olopatadine Hydrochloride | Sensory Organ | Allergic conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.86546695 %) | Approved | 27742486 |
| DrugRepV_2366 | Dorzolamide Hydrochloride | Sensory Organ | Open-angle glaucoma and ocular hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | No significant decrease (2.81420444 %) | Approved | 27742486 |
| DrugRepV_2527 | Acetylcholine Chloride | Sensory Organ | Ophthalmological Disease | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.4447588 %) | Approved | 27742486 |
| DrugRepV_2553 | Loteprednol Etabonate | Sensory Organ | Allergic conjunctivitis | Uveitis | Acne rosacea | Superficial punctate keratitis | Herpes zoster keratitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-0.8962545 %) | Approved | 27742486 |
| DrugRepV_2652 | Nepafenac | Sensory Organ | Inflammation associated with cataract surgery | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.1896457 %) | Approved | 27742486 |
| DrugRepV_2657 | Bimatoprost | Sensory Organ | Ocular Hypertension | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.2748636 %) | Approved | 27742486 |
| DrugRepV_2695 | Atropine | Sensory Organ | Cholinesterase | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9146303 %) | Approved | 27742486 |
| DrugRepV_2701 | Pranoprofen | Sensory Organ | NA | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-2.9707089 %) | Experimental, Investigational | 27742486 |
| DrugRepV_2703 | Dichlorphenamide | Sensory Organ | Glaucoma | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.006092 %) | Approved | 27742486 |
| DrugRepV_2722 | Besifloxacin Hydrochloride | Sensory Organ | Bacterial conjunctivitis | Chikungunya virus | vAc-CHIKV 26S-Rhir-E | NA | Fusion index-Fluorescent Intensities | Increase (-3.332664 %) | Approved | 27742486 |
| DrugRepV_8152 | Trifluridine | Sensory Organ | Primary keratoconjunctivitis and Herpes simplex keratitis | Vaccinia virus | NA | | NA | Decrease (99.9 %) | Approved | 32708182 |